The nasal formulation facilitates studies involving mucosal absorption and delivery mechanisms in vitro and ex vivo models
Although nanoformulations have demonstrated potential in these areas, -secretase inhibition has been associated with significant adverse effects due to its involvement in multiple physiological processes
This makes it a convenient option for those with busy schedules
are pregnant or breastfeeding or plan to become pregnant or breastfeed
The animal literature is unusually consistent, though: nearly every published in vivo study used 5 mg/kg per injection, given three times on alternate days (days 1, 3, and 5, or days 14, 16, and 18 in the pulmonary fibrosis model), with effects tracked over the following three to four weeks
These areas often benefit significantly from regular treatment